NanoViricides, Inc. (OTC BB: NNVC.OB)

Turning Pennies into dollars: NanoViricides, Inc. (OTC BB: NNVC.OB)

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/nnvc

Monday April 6, 2009, 7:00 am EDT

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), is providing a summary of its achievements over the past 12 months.

Most significantly, the Company reported in June, 2008, that animals treated with its anti-HIV lead drug candidate exhibited survival time superior to that of animals treated with the standard three drug oral cocktail called HAART. These studies employed the well established SCID-Hu Thy/Liv mouse model and were conducted by KARD Scientific, Inc. The Company plans to perform additional studies to obtain further detailed information regarding the effect of the nanoviricide drug candidates on HIV in vivo.

NanoViricides, Inc. has reported in May, 2008, that its anti-EKC (epidemic keratoconjunctivitis) drug candidate exhibited excellent clinical improvement in an ophthalmic adenovirus infection animal model of this disease. These studies were conducted by scientists at the Feinstein Institute of Medical Research (FIMR), part of the North Shore-LIJ Health System. These studies were presented by the FIMR scientists at the 42nd annual meeting of the Ocular Microbiology and Immunology Group (OMIG) in Atlanta, Georgia, in November 2008. In addition, evaluation of our ophthalmic anti-herpes nanoviricide drug candidates will begin shortly at a renowned School of Veterinary Medicine in the US.

The Company further reports satisfactory progress in its anti-Rabies program. These studies are continuing at the US Centers for Diseases Control and Prevention (CDC).

The Company is presently in discussions with an independent research facility to perform anti-H5N1 animal studies with the Company’s drug candidates that were highly successful against H5N1 Clade 1 and Clade 2 in cell cultures. These nanoviricides were also found to be highly effective against common influenza (H1N1) in animal models.

The Company has previously reported positive results for its Ebola program. The first part of the program consisted of cell culture studies of the effect of nanoviricides against Ebola virus. Several nanoviricide drug candidates showed very high efficacy against Ebola in these studies. These studies were conducted by scientists at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID). Subsequently, the Company was invited to submit a grant application to the TMTI program of the Department of Defense (DoD) and did so this January. The objective of the grant application is to further develop both the Ebola and Dengue programs of the Company. The DoD is interested in further development of our broad-spectrum nanoviricides in order to minimize stockpiling costs while still achieving high efficacies against a broad range of viruses.

The Company previously reported that it has signed certain agreements regarding further development of its eye drug candidate. In addition, several other potential collaboration partners have expressed a strong interest in pursuing co-development opportunities for the Company’s other drug candidates. The Company is actively pursuing these opportunities.

“We have attained strong positive achievements in the past twelve months in all of our drug development programs,” said Eugene Seymour, MD, MPH, CEO of the Company, adding, “We are confident that we will achieve further successes in our drug development and commercialization programs during the next calendar year as well.”

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.



Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com

 

 

(OTCBB:NNVC) NanoViricides, Inc

Turning Pennies into dollars: (OTCBB:NNVC) NanoViricides, Inc

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147

For more info: http://www.realpennies.com/otc/nnvc

NanoViricides, Inc. Update on Eye Drug Development

(OTCBB:NNVC) NanoViricides, Inc.

NanoViricides, Inc. Update on Eye Drug Development

Monday February 9, 7:00 am ET

WEST HAVEN, Conn.-NanoViricides, Inc. , reported recently that on-going negotiations with a large pharmaceutical company have now progressed to an advanced stage. The pharmaceutical company initially plans to evaluate NanoViricides?s drug candidate for effectiveness against external ophthalmic diseases caused by two different virus types, namely herpes simplex virus and adenovirus. These evaluations will be performed by an independent research institute that specializes in diseases of the eye.

HSV and some adenoviruses cause most of the cases of keratitis, a serious infection of the cornea. Importantly, HSV infection can lead to corneal scarring that may necessitate corneal transplantation. In addition, some adenoviruses cause a majority of conjunctivitis cases . The remaining cases of conjunctivitis, caused by bacteria, are treatable with topical antibiotics. Currently, there are no effective treatments for viral diseases of the exterior portion of the eye.

The Company has already demonstrated strong efficacy against an adenovirus-caused external eye disease called epidemic kerato-conjunctivitis . Rapid clinical improvement in the treated animals was reported by independent researchers who tested the effects of the nanoviricides drug candidate against adenoviral EKC. Based on computer modeling, the Company believes that the broad-spectrum nature of the ligand used in this nanoviricide should enable it to be effective against HSV.

The total market for viral conjunctivitis is estimated to be in the billions of dollars. The incidence of severe herpes keratitis is estimated to be 250,000 cases per year in the USA. In Japan, where EKC is a reportable disease, it is estimated that there are at least one million cases per year. The number of cases of non-specific conjunctivitis is considered to be far greater, possibly into tens of millions in the US, and into hundreds of millions worldwide.

The Company will need to procure large quantities of the nanoviricides drug candidates for the upcoming studies. In order to support this production scale, TheraCour Pharma, Inc., the Company?s largest shareholder and licensor of the technology that the Company uses in its anti-viral drug development, has initiated a program to expand its laboratory facilities. TheraCour has entered into a Rule 10b5-1 trading plan to sell, over a one year period, up to 1.8 million shares of the Company?s common stock that it owns. The proceeds are to be used to pay for the necessary improvements in laboratory facilities, the purchase of analytical equipment, and the costs of intellectual property protection.

?NanoViricides will benefit from the advanced instrumentation that TheraCour plans to purchase without having to make the capital expenditure itself,? said Eugene Seymour, MD, MPH, CEO of NanoViricides, adding, ?Availability of larger quantities of our drug candidates will greatly expedite our drug development for a number of different viral diseases. This should accelerate our efforts to move our drugs into the FDA approval process.?

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide? class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Contact:

NanoViricides, Inc. Amanda Schuon, 310-550-7200 info@nanoviricides.com Source: NanoViricides, Inc.

Profile for NanoViricides, Inc.

NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus , Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company’s products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide ... Detailed NNVC Company Description...

LAST $0.70 USD

Find out more about NNVC

Realpennies.com

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com

(OTCBB:NNVC) NanoViricides, Inc.

Turning Pennies into dollars: (OTCBB:NNVC) NanoViricides, Inc.

Are you a public company looking for exposure?

Contact RealPennies.com - 212-662-2147



For more info: http://www.realpennies.com/otc/nnvc

NanoViricides, Inc. Submits a Grant Application for Broad-Spectrum Nanoviricides

(OTCBB:NNVC) NanoViricides, Inc.

Sunday February 1, 11:20 pm ET

If Approved, Could Finance Dengue and Ebola/Marburg Drug Development

WEST HAVEN, Conn.-NanoViricides, Inc. , said that it has recently submitted a grant application to the Department of Defense. This grant, if awarded, will be used for the development of broad-spectrum nanoviricides drugs. If successful, a broad-spectrum nanoviricide could be employed as an important Medical CounterMeasure against bio-terrorism and emerging infectious diseases such as Ebola/Marburg, and Dengue.

The Company has already demonstrated that some of the nanoviricides we have created are broad-spectrum. It is believed that viruses are unlikely to escape such broad-spectrum nanoviricides by mutation because such mutations would also cause a loss of infectivity.

At present, other MCM efforts have generally resulted in highly specific one-bug-one-drug type of therapies, such as vaccines, antibodies, certain anti-sense therapeutics, and some other antivirals. Thus, a large number of drugs, vaccines and antibodies would need to be stockpiled to mitigate the threat from a countless number of pathogens and their known mutants. Further, if a virus mutates further, then most such agents are likely to become ineffective. Mutations are common in many viruses, and can also be genetically engineered to produce devastating bio-terrorism agents.

The Company has assembled a strong team comprising several renowned Institutions and Companies for the proposed project. There is no guarantee that the grant application will result in any funding.

Ebola viruses cause devastating disease with mortality rates as high as 90%. Dengue has now become endemic in most of the tropical world, and is becoming an important public health threat in the United States. A second infection from an unrelated dengue virus subtype can be life-threatening, resulting in dengue hemorrhagic fever or dengue shock syndrome . There is currently no drug or vaccine available for dengue viruses. The worldwide market for a dengue treatment could be possibly in the billions of dollars.

About NanoViricides:

NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide? class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are ?forward-looking statements? within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the ?Management?s Discussion and Analysis? section of the Company?s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

Contact:

NanoViricides, Inc. Amanda Schuon, 310-550-7200 info@nanoviricides.com Source: NanoViricides, Inc.

Profile for NanoViricides, Inc.

NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus , Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company’s products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide ... Detailed NNVC Company Description...

LAST $0.71 USD



Realpennies.com



Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on

http://www.realpennies.com/start.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice. This may contain forward-looking statements and are not guarantees of performance. Reproduction of this without written permission is prohibited.

RealPennies.com

Phone: 212-662-2147

info [at] realpennies.com